Pattern of rash, diarrhea, and hepatic toxicities secondary to lapatinib and their association with age and response to neoadjuvant therapy: analysis from the NeoALTTO trial.
about
Dual HER2 blockade in the neoadjuvant and adjuvant treatment of HER2-positive breast cancerNeratinib in HER-2-positive breast cancer: results to date and clinical usefulnessMechanism-based inactivation of CYP450 enzymes: a case study of lapatinibSystemic targeted therapy for her2-positive early female breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guidelineEfficacy and Safety of HER2-Targeted Agents for Breast Cancer with HER2-Overexpression: A Network Meta-AnalysisDevelopment of the rat model of lapatinib-induced diarrhoea.Systematic Review of the Side Effects Associated With Anti-HER2-Targeted Therapies Used in the Treatment of Breast Cancer, on Behalf of the EORTC Quality of Life Group.DEGRO practical guidelines for radiotherapy of breast cancer V: Therapy for locally advanced and inflammatory breast cancer, as well as local therapy in cases with synchronous distant metastases.A Pilot Study of Dose-Dense Paclitaxel With Trastuzumab and Lapatinib for Node-negative HER2-Overexpressed Breast Cancer.Dermatologic events from EGFR inhibitors: the issue of the missing patient voice.Efficacy and safety of lapatinib and trastuzumab for HER2-positive breast cancer: a systematic review and meta-analysis of randomised controlled trialsTargeted therapy of kidney cancer: keeping the art around the algorithms.Adjuvant systemic treatment for elderly breast cancer patients; addressing safety concerns.Cancer therapy-related complications in the bowel and mesentery: an imaging perspective.Prognostic value of endocrine treatment-related symptoms in patients with breast cancer: a meta-analysis.Lapatinib-Related Rash and Breast Cancer Outcome in the ALTTO Phase III Randomized Trial.Pigmentation of the Tongue with Lapatinib Treatment in a Patient with Advanced Breast Cancer: A Case Report.Cytochrome P450 3A4 and CYP3A5-Catalyzed Bioactivation of LapatinibRash in lapatinib-treated patients is not associated with human leukocyte antigen polymorphisms.Lapatinib-associated mucocutaneous toxicities are clinical predictors of improved progression-free survival in patients with human epidermal growth factor receptor (HER2)-positive advanced breast cancer.
P2860
Q26785612-9C9D399E-46D9-4B1B-B96B-FA96004BAB3DQ28071303-F0CFB145-8A23-4194-B9B5-44C07624C67BQ28080497-F75DBF90-F7C9-4B20-A13F-6DB15CDA32C7Q28260063-5B56AC5F-CD64-4B66-A03C-DC5442598303Q28547354-284A4ECE-DEE6-4660-8F1A-50EF48E2FD7AQ33999288-EBF31378-8AD2-4649-89A6-9A9E39F1DBD5Q35871467-63878596-A9AA-44BC-B693-2BE4C8E8DC3EQ35894515-001B8B58-5051-41B2-A81A-8F8929906E2DQ37143133-F15B0B89-3E66-4042-BD38-6736A58B33B4Q37541523-938E6FD9-558B-48E5-A5BB-75634A4791C9Q37704313-24B3F11C-60A3-4E0A-A8DB-17BD0597A741Q38118060-3B4DE616-C950-4808-A78A-E75436C67334Q38253136-FD54DA59-7176-441E-81C7-B6A531929B1EQ38859253-1A3BC208-1FBD-409D-835A-A3D5A080D871Q38963111-2A63EBED-48EC-49A4-992F-5DC00099C5E6Q39836265-68EBC7F4-C0B4-49E0-AD2A-0DAC13BFC1BDQ40319145-F41390B3-D715-45F1-ACC0-927B34C1F9FCQ41640449-1D09AAB7-F5A5-4F59-81F9-F9D588FC80FAQ53201873-F84435AD-C7B6-4267-8702-D0B640D0A13EQ55070923-5720CB66-123B-4E5E-B34E-AF7265F93219
P2860
Pattern of rash, diarrhea, and hepatic toxicities secondary to lapatinib and their association with age and response to neoadjuvant therapy: analysis from the NeoALTTO trial.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Pattern of rash, diarrhea, and ...... lysis from the NeoALTTO trial.
@en
Pattern of rash, diarrhea, and ...... lysis from the NeoALTTO trial.
@nl
type
label
Pattern of rash, diarrhea, and ...... lysis from the NeoALTTO trial.
@en
Pattern of rash, diarrhea, and ...... lysis from the NeoALTTO trial.
@nl
prefLabel
Pattern of rash, diarrhea, and ...... lysis from the NeoALTTO trial.
@en
Pattern of rash, diarrhea, and ...... lysis from the NeoALTTO trial.
@nl
P2093
P2860
P50
P356
P1476
Pattern of rash, diarrhea, and ...... lysis from the NeoALTTO trial.
@en
P2093
Christian Jackisch
Dominique Agbor-Tarh
Hatem A Azim
Holger Eidtmann
Ian Bradbury
James G Greger
Lydia Dreosti
Martine Piccart
Peter Vuylsteke
P2860
P304
P356
10.1200/JCO.2013.50.9448
P407
P577
2013-11-18T00:00:00Z